The Food and Drug Administration yesterday required updated labeling for opioid pain medicine and medicine to treat opioid use disorder to recommend that prescribers discuss naloxone with patients and caregivers.

“Today’s action can help further raise awareness about this potentially life-saving treatment for individuals that may be at greater risk of an overdose and those in the community most likely to observe an overdose,” said FDA Commissioner Stephen Hahn, M.D.

Related News Articles

Headline
Eighty organizations in 36 states and two territories, including some hospitals and health systems, will receive close to $25 million in grants through the…
Headline
State Opioid Response and Tribal Opioid Response grant programs are receiving the first of two rounds of funds totaling $1.5 billion, the Department of Health…
Headline
At Dell Seton Medical Center, clinicians observed that patients with opioid use disorder had a high likelihood of readmission because its underlying causes…
Headline
The Health Resources and Services Administration yesterday awarded 89 organizations, including hospitals, $1 million each to combat opioid and other substance…
Headline
The Substance Abuse and Mental Health Services Administration’s Office of Behavioral Health Equity recently published a report on the opioid crisis’ impact on…
Headline
Drug overdose deaths in the United States rose 4.6% in 2019 to 70,980, including 50,042 involving opioids, according to preliminary data released yesterday by…